Marshall Wace Asia’s AbbVie ABBV Stock Holding History

Marshall Wace Asia’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-20,484	Closed	-$2.22M	–	138
2021 Q1	$2.22M	Buy	+20,484	New	+$2.19M	0.05%	103

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Marshall Wace Asia's ABBV Position: Q2 2021 in Review

Marshall Wace Asia sold out of AbbVie (ABBV) in Q2 2021, closing a stake of 20,484 shares — an estimated $2.22M sold.

Marshall Wace Asia first reported a position in ABBV in Q1 2021 and held it in 1 quarter. The position peaked at $2.22M in Q1 2021. 2,677 funds tracked by Wall St. Rank hold ABBV as of Q2 2021.

Marshall Wace Asia reported no remaining AbbVie position as of Q2 2021 after selling out during the quarter.
Marshall Wace Asia sold 20,484 AbbVie shares in Q2 2021, an estimated $2.22M.
Marshall Wace Asia first reported a position in AbbVie in Q1 2021 and held it in 1 quarter.
Marshall Wace Asia's AbbVie position peaked at $2.22M in Q1 2021.
2,677 funds tracked by Wall St. Rank held AbbVie as of Q2 2021.

Based on Marshall Wace Asia's 13F filing for Q2 2021, filed 13 Aug 2021.